Toxins: Bacterial and Marine Toxins

Clinics in Laboratory Medicine

Volumn 26, Issue 2, 2006, Pages 397-419

  Salzman, Matthew ^a   Madsen, James M ^b   Greenberg, Michael I ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTHRAX TOXIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BACTERIAL VACCINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM ANTISERUM; BOTULINUM TOXIN; CHOLERA TOXIN; CHOLERA VACCINE; CIPROFLOXACIN; COTRIMOXAZOLE; DIAZEPAM; DOXYCYCLINE; ERYTHROMYCIN; GONYAUTOXIN; IMMUNOGLOBULIN; LETHAL FACTOR INHIBITOR; MAGNESIUM SULFATE; MARINE TOXIN; METRONIDAZOLE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETANUS TOXIN; TETANUS TOXOID; TETRODOTOXIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEROTOXIN;

AIRWAY OBSTRUCTION; ANTHRAX; ANTIBIOTIC THERAPY; ANTINEOPLASTIC ACTIVITY; ANUS FISSURE; ARTIFICIAL VENTILATION; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; BLEPHAROSPASM; BOTULISM; CARDIOTOXICITY; CELLULAR IMMUNITY; CHOLERA; CLOSTRIDIUM TETANI; CYTOKINE RELEASE; CYTOPATHOLOGY; DENDRITIC CELL; DETOXIFICATION; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DRUG POTENCY; ELECTROLYTE BALANCE; ENDOTRACHEAL INTUBATION; EPIDEMIC; FACIAL NERVE PARALYSIS; FOOD CONTAMINATION; HELPER CELL; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMORAL IMMUNITY; HYPERHIDROSIS; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION PREVENTION; LD 50; LETHAL GENE; LOCAL ANESTHESIA; MULTIPLE SCLEROSIS; MUSCLE SPASM; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OPISTHOTONUS; PAIN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SHIGELLA DYSENTERIAE; SHIGELLOSIS; SKIN INFECTION; STRABISMUS; T LYMPHOCYTE ACTIVATION; TETANUS; TOXICOKINETICS; UNITED STATES; VITAMIN SUPPLEMENTATION; WRINKLE;

BACTERIAL TOXINS; BIOTERRORISM; HUMANS; MARINE TOXINS;

EID: 33745426024     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2006.04.003     Document Type: Review

References (136)

1. Madsen J. Toxins as weapons of mass destruction. A comparison and contrast with biological warfare and chemical warfare agents. Clin Lab Med 21 3 (2001) 593-605
2. Shapiro DS WA. Sentinel laboratory guidelines for suspected agents of bioterrorism. Botulinum. Available at: http://www.asm.org/ASM/files/LEFTMARGINHEADERLIST/downloadfilename/0000000522/BotulismFinalVersion73003.pdf. Accessed January 6, 2006.
3. Centers for Disease Control and Prevention. Botulism in the United States, 1899-1996. Handbook for epidemiologists, clinicians and laboratory workers (1998), Centers for Disease Control and Prevention, Atlanta (GA)
4. Aktories K., and Barth H. Clostridium botulinum C2 toxin-new insights into the cellular up-take of the actin-ADP-ribosylating toxin. Int J Med Microbiol 293 7-8 (2004) 557-564
5. Caya J.G., Agni R., and Miller J.E. Clostridium botulinum and the clinical laboratorian: a detailed review of botulism, including biological warfare ramifications of botulinum toxin. Arch Pathol Lab Med 128 6 (2004) 653-662
6. Barash J.R., Tang T.W., and Arnon S.S. First case of infant botulism caused by Clostridium baratii type F in California. J Clin Microbiol 43 8 (2005) 4280-4282
7. Centers for Disease Control and Prevention. Botulism outbreak associated with eating fermented foods-Alaska, 2001. MMWR Morb Mortal Wkly Rep 50 32 (2001) 680-682
8. Liu W., Montana V., Chapman E.R., et al. Botulinum toxin type B micromechanosensor. Proc Natl Acad Sci USA 100 23 (2003) 13621-13625
9. Parpura V., and Chapman E.R. Detection of botulinum toxins: micromechanical and fluorescence-based sensors. Croat Med J 46 4 (2005) 491-497
10. Centers for Disease Control and Prevention. Wound botulism-California, 1995. MMWR Morb Mortal Wkly Rep 44 48 (1995) 889-892
11. Goetz C.G., and Meisel E. Selected classic examples of neurotoxic disorders-biological neurotoxins. Neurol Clin 18 3 (2000) 719-740
12. Marks J.D. Medical aspects of biologic toxins. Anesthesiol Clin North America 22 3 (2004) 509-532 vii
13. Bioterriorism Agents/Diseases by Category. Available at: http://www.bt.cdc.gov/agent/agentlist-category.asp. Accessed January 3, 2006.
14. Darling RG WJ. USAMRIID's medical management of biological casualties handbook. 5th edition. Frederick (MD): US Army Medical Research Institute; 2004.
15. Ahn-Yoon S., DeCory T.R., and Durst R.A. Ganglioside-liposome immunoassay for the detection of botulinum toxin. Anal Bioanal Chem 378 1 (2004) 68-75
16. Arnon S.S., Schechter R., Inglesby T.V., et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285 8 (2001) 1059-1070
17. Schiavo G., Benfenati F., Poulain B., et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359 6398 (1992) 832-835
18. Schiavo G., Shone C.C., Rossetto O., et al. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem 268 16 (1993) 11516-11519
19. Dressler D., Saberi F.A., and Barbosa E.R. Botulinum toxin: mechanisms of action. Eur Neurol 63 1 (2005) 180-185
20. Montecucco C., and Molgo J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 5 3 (2005) 274-279
21. Moorthy J., Mensing G.A., Kim D., et al. Microfluidic tectonics platform: a colorimetric, disposable botulinum toxin enzyme-linked immunosorbent assay system. Electrophoresis 25 10-11 (2004) 1705-1713
22. Chiao D.J., Shyu R.H., Hu C.S., et al. Colloidal gold-based immunochromatographic assay for detection of botulinum neurotoxin type B. J Chromatogr B Analyt Technol Biomed Life Sci 809 1 (2004) 37-41
23. Barr J.R., Moura H., Boyer A.E., et al. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis 11 10 (2005) 1578-1583
24. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. The Pink Book. 8th edition. Available at: http://www.cdc.gov/nip/publications/pink. Accessed January 4, 2006.
25. Montecucco C., and Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 13 1 (1994) 1-8
26. Goonetilleke A., and Harris J.B. Clostridial neurotoxins. J Neurol Neurosurg Psychiatry 75 Suppl 3 (2004) iii35-iii39
27. Pascual FB ME, Zanardi LR, Cortese MM, et al. Tetanus surveillance-United States 1998-2000. MMWR CDC Surveill Summ 2003;52(SS03):1-8.
28. Thwaites C.L., and Farrar J.J. Preventing and treating tetanus. BMJ 326 7381 (2003) 117-118
29. Akbulut D., Grant K.A., and McLauchlin J. Improvement in laboratory diagnosis of wound botulism and tetanus among injecting illicit-drug users by use of real-time PCR assays for neurotoxin gene fragments. J Clin Microbiol 43 9 (2005) 4342-4348
30. Shoop W.L., Xiong Y., Wiltsie J., et al. Anthrax lethal factor inhibition. Proc Natl Acad Sci USA 102 22 (2005) 7958-7963
31. Collier R.J., and Young J.A. Anthrax toxin. Annu Rev Cell Dev Biol 19 (2003) 45-70
32. Brossier F., and Mock M. Toxins of Bacillus anthracis. Toxicon 39 11 (2001) 1747-1755
33. Petosa C., Collier R.J., Klimpel K.R., et al. Crystal structure of the anthrax toxin protective antigen. Nature 385 6619 (1997) 833-838
34. Gordon V.M., Klimpel K.R., Arora N., et al. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun 63 1 (1995) 82-87
35. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 79 10 (1982) 3162-3166
36. Tournier J.N., Quesnel-Hellmann A., Mathieu J., et al. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J Immunol 174 8 (2005) 4934-4941
37. Paccani S.R., Tonello F., Ghittoni R., et al. Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J Exp Med 201 3 (2005) 325-331
38. Klimpel K.R., Arora N., and Leppla S.H. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol Microbiol 13 6 (1994) 1093-1100
39. Duesbery N.S., Webb C.P., Leppla S.H., et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280 5364 (1998) 734-737
40. Park J.M., Greten F.R., Li Z.W., et al. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 297 5589 (2002) 2048-2051
41. Kirby J.E. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect Immun 72 1 (2004) 430-439
42. Questions and answer about anthrax. Available at: http://www.bt.cdc.gov/agent/anthrax/faq. Accessed December 10, 2005.
43. Inglesby T.V., O'Toole T., Henderson D.A., et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287 17 (2002) 2236-2252
44. Approved tests for the detection of Bacillus anthracis in the laboratory response network. Available at: http://www.bt.cdc.gov/agent/anthrax/lab-testing/approvedlrntests.asp. Accessed January 3, 2006.
45. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 50 42 (2001) 909-919
46. Dalsgaard A., Serichantalergs O., Forslund A., et al. Clinical and environmental isolates of Vibrio cholerae serogroup O141 carry the CTX phage and the genes encoding the toxin-coregulated pili. J Clin Microbiol 39 11 (2001) 4086-4092
47. Sixma T.K., Kalk K.H., van Zanten B.A., et al. Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J Mol Biol 230 3 (1993) 890-918
48. Zhang R.G., Scott D.L., Westbrook M.L., et al. The three-dimensional crystal structure of cholera toxin. J Mol Biol 251 4 (1995) 563-573
49. Holmgren J., Lonnroth I., Mansson J., et al. Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc Natl Acad Sci USA 72 7 (1975) 2520-2524
50. Fujinaga Y., Wolf A.A., Rodighiero C., et al. Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulum. Mol Biol Cell 14 12 (2003) 4783-4793
51. Lencer W.I. Retrograde transport of cholera toxin into the ER of host cells. Int J Med Microbiol 293 7-8 (2004) 491-494
52. Cassel D., and Selinger Z. Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site. Proc Natl Acad Sci USA 74 8 (1977) 3307-3311
53. Rodighiero C., Aman A.T., Kenny M.J., et al. Structural basis for the differential toxicity of cholera toxin and Escherichia coli heat-labile enterotoxin. Construction of hybrid toxins identifies the A2-domain as the determinant of differential toxicity. J Biol Chem 274 7 (1999) 3962-3969
54. Lu L., Baldeon M.E., Savidge T., et al. Development of microbial-human enterocyte interaction: cholera toxin. Pediatr Res 54 2 (2003) 212-218
55. Bopp CA RA, Wells JG. Laboratory methods for the diagnosis of epidemic dysentery and cholera. Atlanta (GA): Centers for Disease Control and Prevention; 1999.
56. Centers for Disease Control and Prevention. Current trends update: cholera-Western Hemisphere, and recommendations for treatment of cholera. MMWR Morb Mortal Wkly Rep 40 32 (1991) 562-565
57. Centers for Disease Control and Prevention. Update on cholera vaccine. Available at: http://www.cdc.gov/travel/other/cholera-vaccine.htm. Accessed January 4, 2006.
58. Karch H. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)-associated hemolytic-uremic syndrome. Semin Thromb Hemost 27 3 (2001) 207-213
59. Watanabe M., Matsuoka K., Kita E., et al. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J Infect Dis 189 3 (2004) 360-368
60. Obrig T.G., Louise C.B., Lingwood C.A., et al. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 268 21 (1993) 15484-15488
61. Sherman P., Soni R., and Karmali M. Attaching and effacing adherence of Vero cytotoxin-producing Escherichia coli to rabbit intestinal epithelium in vivo. Infect Immun 56 4 (1988) 756-761
62. Cherla R.P., Lee S.Y., and Tesh V.L. Shiga toxins and apoptosis. FEMS Microbiol Lett 228 2 (2003) 159-166
63. Endo Y., Tsurugi K., Yutsudo T., et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 171 1-2 (1988) 45-50
64. Obrig T.G., Moran T.P., and Brown J.E. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 244 2 (1987) 287-294
65. Yoshida T., Koide N., Sugiyama T., et al. A novel caspase dependent pathway is involved in apoptosis of human endothelial cells by Shiga toxins. Microbiol Immunol 46 10 (2002) 697-700
66. Colpoys W.E., Cochran B.H., Carducci T.M., et al. Shiga toxins activate translational regulation pathways in intestinal epithelial cells. Cell Signal 17 7 (2005) 891-899
67. Thorpe C.M. Shiga toxin-producing Escherichia coli infection. Clin Infect Dis 38 9 (2004) 1298-1303
68. Centers for Disease Control and Prevention. Escherichia coli O157:H7 outbreak linked to home-cooked hamburger-California, July 1993. MMWR Morb Mortal Wkly Rep 43 12 (1994) 213-216
69. Siegler R. Central nervous system involvement in the hemolytic uremic syndrome. In: Kaplan B.S., Trompeter R.S., and Moake J.L. (Eds). Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura (1992), Marcel Dekker, New York
70. Wong C.S., Jelacic S., Habeeb R.L., et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342 26 (2000) 1930-1936
71. Kimmitt P.T., Harwood C.R., and Barer M.R. Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis 6 5 (2000) 458-465
72. Centers for Disease Control and Prevention. University outbreak of calicivirus infection mistakenly attributed to shiga toxin-producing Escherichia coli O157:H7-Virginia, 2000. MMWR Morb Mortal Wkly Rep 50 23 (2001) 489-491
73. Braden CLJ, Boothe E, Vugia D, et al. Testing to identify shiga toxin-producing E. coli in HUS patients: FoodNet 1997-2001. Presented at the International Conference on Emerging Infectious Diseases. Atlanta (GA), March 2002.
74. Isbister G.K., and Kiernan M.C. Neurotoxic marine poisoning. Lancet Neurol 4 4 (2005) 219-228
75. Lange W.R., Lipkin K.M., and Yang G.C. Can ciguatera be a sexually transmitted disease?. J Toxicol Clin Toxicol 27 3 (1989) 193-197
76. Lehane L. Ciguatera fish poisoning: a review in a risk-assessment framework (1999), National Office of Animal and Plant Health, Agriculture, Fisheries and Forestry, Canberra (Australia)
77. Mattei C., Molgo J., Marquais M., et al. Hyperosmolar D-mannitol reverses the increased membrane excitability and the nodal swelling caused by Caribbean ciguatoxin-1 in single frog myelinated axons. Brain Res 847 1 (1999) 50-58
78. Lehane L., and Lewis R.J. Ciguatera: recent advances but the risk remains. Int J Food Microbiol 61 2-3 (2000) 91-125
79. International Programme on Chemical Safety. Environmental health criteria 37. Aquatic (marine and freshwater) biotoxins. Available at: http://www.inchem.org/documents/ehc/ehc/ehc37.htm. Accessed January 4, 2006.
80. Centers for Disease Control and Prevention. Ciguatera fish poisoning-Texas, 1997. MMWR Morb Mortal Wkly Rep 43 33 (1998) 692-694
81. Lewis R.J. The changing face of ciguatera. Toxicon 39 1 (2001) 97-106
82. Oliver L. Recommendations for use of the Cigua-check test kit. Presented at the Fourth Workshop of the Australian Research Network for Algal Toxins (ARNAT). Townsville, Queensland, Australia. The Australian Institute of Marine Science, July 14, 2002.
83. Matta J., Navas J., Milad M., et al. A pilot study for the detection of acute ciguatera intoxication in human blood. J Toxicol Clin Toxicol 40 1 (2002) 49-57
84. Palafox N.A., Jain L.G., Pinano A.Z., et al. Successful treatment of ciguatera fish poisoning with intravenous mannitol. JAMA 259 18 (1988) 2740-2742
85. Schnorf H., Taurarii M., and Cundy T. Ciguatera fish poisoning: a double-blind randomized trial of mannitol therapy. Neurology 58 6 (2002) 873-880
86. Jeffery B., Barlow T., Moizer K., et al. Amnesic shellfish poison. Food Chem Toxicol 42 4 (2004) 545-557
87. Brown J.A., and Nijjar M.S. The release of glutamate and aspartate from rat brain synaptosomes in response to domoic acid (amnesic shellfish toxin) and kainic acid. Mol Cell Biochem 151 1 (1995) 49-54
88. Stewart G.R., Zorumski C.F., Price M.T., et al. Domoic acid: a dementia-inducing excitotoxic food poison with kainic acid receptor specificity. Exp Neurol 110 1 (1990) 127-138
89. Ravn H YT, Ramsdell T. Amnestic shellfish poisoning (ASP). Intergovernmental Oceanographic Commission HAB publication series 1995;1(31).
90. Peng Y.G., Taylor T.B., Finch R.E., et al. Neuroexcitatory and neurotoxic actions of the amnesic shellfish poison, domoic acid. Neuroreport 5 8 (1994) 981-985
91. Kizer K.W. Domoic acid poisoning. West J Med 161 1 (1994) 59-60
92. Kawatsu K., Hamano Y., and Noguchi T. Production and characterization of a monoclonal antibody against domoic acid and its application to enzyme immunoassay. Toxicon 37 11 (1999) 1579-1589
93. Perl T.M., Bedard L., Kosatsky T., et al. An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med 322 25 (1990) 1775-1780
94. Teitelbaum J.S., Zatorre R.J., Carpenter S., et al. Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 322 25 (1990) 1781-1787
95. Cendes F., Andermann F., Carpenter S., et al. Temporal lobe epilepsy caused by domoic acid intoxication: evidence for glutamate receptor-mediated excitotoxicity in humans. Ann Neurol 37 1 (1995) 123-126
96. Smith D.S., and Kitts D.D. A competitive enzyme-linked immunoassay for domoic acid determination in human body fluids. Food Chem Toxicol 32 12 (1994) 1147-1154
97. International Programme on Chemical Safety. Poisons information monograph 67. Available at: http://www.inchem.org/documents/pims/chemical/pim670.htm. Accessed January 4, 2006.
98. Pinsky C., Glavin G.B., and Bose R. Kynurenic acid protects against neurotoxicity and lethality of toxic extracts from contaminated Atlantic coast mussels. Prog Neuropsychopharmacol Biol Psychiatry 13 3-4 (1989) 595-598
99. Naar J., Bourdelais A., Tomas C., et al. A competitive ELISA to detect brevetoxins from Karenia brevis (formerly Gymnodinium breve) in seawater, shellfish, and mammalian body fluid. Environ Health Perspect 110 2 (2002) 179-185
100. Cheng Y.S., McDonald J.D., Kracko D., et al. Concentration and particle size of airborne toxic algae (brevetoxin) derived from ocean red tide events. Environ Sci Technol 39 10 (2005) 3443-3449
101. Baden D.G., Bourdelais A.J., Jacocks H., et al. Natural and derivative brevetoxins: historical background, multiplicity, and effects. Environ Health Perspect 113 5 (2005) 621-625
102. Bottein Dechraoui M.Y., and Ramsdell J.S. Type B brevetoxins show tissue selectivity for voltage-gated sodium channels: comparison of brain, skeletal muscle and cardiac sodium channels. Toxicon 41 7 (2003) 919-927
103. Poli M.A., Mende T.J., and Baden D.G. Brevetoxins, unique activators of voltage-sensitive sodium channels, bind to specific sites in rat brain synaptosomes. Mol Pharmacol 30 2 (1986) 129-135
104. Baden D.G. Brevetoxins: unique polyether dinoflagellate toxins. FASEB J 3 7 (1989) 1807-1817
105. Baden D.G., and Mende T.J. Toxicity of two toxins from the Florida red tide marine dinoflagellate, Ptychodiscus brevis. Toxicon 20 2 (1982) 457-461
106. Baden D.G., Mende T.J., Bikhazi G., et al. Bronchoconstriction caused by Florida red tide toxins. Toxicon 20 5 (1982) 929-932
107. Woofter R., Dechraoui M.Y., Garthwaite I., et al. Measurement of brevetoxin levels by radioimmunoassay of blood collection cards after acute, long-term, and low-dose exposure in mice. Environ Health Perspect 111 13 (2003) 1595-1600
108. Trainer V.L., and Baden D.G. An enzyme immunoassay for the detection of Florida red tide brevetoxins. Toxicon 29 11 (1991) 1387-1394
109. Poli M.A., Musser S.M., Dickey R.W., et al. Neurotoxic shellfish poisoning and brevetoxin metabolites: a case study from Florida. Toxicon 38 7 (2000) 981-993
110. Australia New Zealand Food Authority. Shellfish toxins in food. A toxicological review and risk assessment. Technical report series number 14. p. 13-5. Available at: http://www.anzfa.gov. Accessed January 3, 2005.
111. Sorokin M. Puffer fish poisoning. Med J Aust 1 19 (1973) 957
112. Ahasan H.A., Mamun A.A., Karim S.R., et al. Paralytic complications of puffer fish (tetrodotoxin) poisoning. Singapore Med J 45 2 (2004) 73-74
113. Tetrodotoxin. Available at: http://www.pufferfish.co.uk/aquaria.species/general/tetro.htm. Accessed January 3, 2005.
114. Simidu U., Noguchi T., Hwang D.F., et al. Marine bacteria which produce tetrodotoxin. Appl Environ Microbiol 53 7 (1987) 1714-1715
115. Yu C.F., Yu P.H., Chan P.L., et al. Two novel species of tetrodotoxin-producing bacteria isolated from toxic marine puffer fishes. Toxicon 44 6 (2004) 641-647
116. Tetrodotoxin: essentail data. Available at: http://www.cbwinfo.com/Biological/Toxins/TTX.html. Accessed January 3, 2006.
117. Cestele S., and Catterall W.A. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. Biochimie 82 9-10 (2000) 883-892
118. Kiernan M.C., Isbister G.K., Lin C.S., et al. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol 57 3 (2005) 339-348
119. Lan M.Y., Lai S.L., Chen S.S., et al. Tetrodotoxin intoxication in a uraemic patient. J Neurol Neurosurg Psychiatry 67 1 (1999) 127-128
120. Toxnet. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/∼DPklSV:1. Accessed January 5, 2006.
121. How C.K., Chern C.H., Huang Y.C., et al. Tetrodotoxin poisoning. Am J Emerg Med 21 1 (2003) 51-54
122. O'Leary M.A., Schneider J.J., and Isbister G.K. Use of high performance liquid chromatography to measure tetrodotoxin in serum and urine of poisoned patients. Toxicon 44 5 (2004) 549-553
123. Saxitoxins. Available at: http://www.aims.gov.au/arnat/arnat-0008.htm. Accessed January 9, 2006.
124. Okumura M., Tsuzuki H., and Tomita B. A rapid detection method for paralytic shellfish poisoning toxins by cell bioassay. Toxicon 46 1 (2005) 93-98
125. Dell'Aversano C., Hess P., and Quilliam M.A. Hydrophilic interaction liquid chromatography-mass spectrometry for the analysis of paralytic shellfish poisoning (PSP) toxins. J Chromatogr A 1081 2 (2005) 190-201
126. Garrido R., Lagos N., Lattes K., et al. Gonyautoxin: new treatment for healing acute and chronic anal fissures. Dis Colon Rectum 48 2 (2005) 335-340
127. Su Z., Sheets M., Ishida H., et al. Saxitoxin blocks L-type ICa. J Pharmacol Exp Ther 308 1 (2004) 324-329
128. Wang J., Salata J.J., and Bennett P.B. Saxitoxin is a gating modifier of HERG K+ channels. J Gen Physiol 121 6 (2003) 583-598
129. Flemming LE. Paralytic shellfish poisoning. Available at: http://www.whoi.edu/redtide/illness/psp.html. Accessed January 10, 2006.
130. Saxitoxin. In: Robinson J, editor. Public health response to biological and chemical weapons. WHO guidance. 2nd edition. Geneva (Switzerland): World Health Organization.
131. Lehane L. Paralytic shellfish poisoning: a review (2000), National Office of Animal and Plant Health, Agriculture, Fisheries, and Forestry, Canberra (Australia)
132. Gessner B.D., Bell P., Doucette G.J., et al. Hypertension and identification of toxin in human urine and serum following a cluster of mussel-associated paralytic shellfish poisoning outbreaks. Toxicon 35 5 (1997) 711-722
133. Vangelova L. Botulinum toxin: a poison that can heal. 1998. Available at: www.fda.gov/fdac/features/095_bot.html. Accessed January 3, 2006.
134. Frankel A.E., Powell B.L., Duesbery N.S., et al. Anthrax fusion protein therapy of cancer. Curr Protein Pept Sci 3 4 (2002) 399-407
135. Lavelle E.C., Jarnicki A., McNeela E., et al. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J Leukoc Biol 75 5 (2004) 756-763
136. Nashar T.O., Hirst T.R., and Williams N.A. Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1. Immunology 91 4 (1997) 572-578